Sample in
A raw or minimally conditioned sample enters a disposable cartridge.
Investor introduction
Aevrium Select for IVF-lab confidence.
Aevrium Biosystems is developing Aevrium Select, a consumables-led reproductive microfluidics wedge that delivers a selected sperm fraction plus a point-of-use confidence signal for fertility laboratories.
The seed thesis is disciplined: prove one costly workflow decision first, make the cartridge credible at the bench, then earn the right to expand into a broader reproductive-health platform.
Seed ask$4M product-proof
Time horizon12 months to pilot
Business modelRoutine-use cartridge
PosturePatent-pending
Aevrium Select
Selected fraction plus evidence, not just a chip.
A practical workflow tool: enrich the sample, observe a defined readout zone, score key quality signals, and return an embryologist-facing confidence output — without forcing a complex dashboard into the lab.
Select
The internal system enriches for a better-performing sperm subpopulation.
Observe
A short capture occurs in a defined observation region.
Score
Simple analysis combines motion, cleanliness, and recovery adequacy.
Output
The embryologist receives a fraction plus a confidence signal, with borderline / no-call handling when confidence is weak.
Market opportunity
A narrow wedge into a high-value IVF workflow.
Aevrium does not need to claim the full ART market to matter. The public story focuses on a conservative exposure model for fertilization uncertainty, lab-side burden, and a low-friction adoption path for a routine-use consumable.
449,772U.S. IVF treatment cycles cited in the current investor deck.Used for wedge exposure sizing.
2%–5%Conservative catastrophic-failure band used for framing.Presented as exposure, not guaranteed revenue.
$173M–$432MEstimated U.S. exposed patient spend.Management model; illustrative.
$23M–$63MEstimated U.S. direct lab-cost consumption.Proxy for workflow pain.
IP & defensibility
A patent-safe moat at the workflow-system level.
Public materials intentionally avoid enabling geometry, dimensions, drawings, and operating recipes. The defensibility story is framed around protected workflow logic: selection, validation, preservation, and exclusion layers.
Who advances
Core selection architecture, described at a high level as low-shear, geometry-guided enrichment of a better-performing subpopulation.
Who is preserved
Validation-gated capture and path closure make validation operationally meaningful rather than merely observational.
Who is kept out
Selective exclusion reduces admixture without requiring public disclosure of device-enabling details.
Fareban-linked provenance
Aevrium is presented as a Fareban operating company, preserving a non-enabling public disclosure posture suitable for a patent-pending company.
Disclosure-safeWhat counts as proof
The wedge has to win at the bench, not only in CAD.
The product-proof program measures what matters for adoption: selection delta, gentle handling, objective validation, and routine workflow fit — deliberately avoiding premature clinical-outcome claims before benchmark and usability data exist.
Better selection delta
Demonstrate enrichment, cleanliness, and usable recovery versus current prep logic.
Low-shear handling
Preserve a gentle microenvironment in a disposable cartridge that runs reliably at the bench.
Objective validation
Generate practical readouts embryologists can trust without adding dashboard complexity.
No workflow friction
Score operator burden, chamber gentleness, recovery practicality, and ease of use as first-tier metrics.
$4M seed plan
Twelve months to named product-proof outputs.
The seed round converts Aevrium from a promising microfluidics program into a benchmarked, pilot-ready product package. Capital is allocated to product-DNA decisioning, head-to-head wedge proof, and pilot readiness.
Product-DNA decision
Fabricate a comparator set, complete gated downselection, issue a Winning Geometry Decision Memo, and lock the product-defining architecture with a viable backup branch.
Head-to-head wedge proof
Benchmark against current prep logic, confirm repeatability, and lock the usability package around operator simplicity, chamber gentleness, and recovery practicality.
Pilot readiness
Prepare the pilot-ready cartridge package, friendly-lab materials, pilot protocol, and commercial narrative around benchmark and usability evidence.
0–3 months
Build & dry-fluidic readiness
Comparator fabricated; priming, bubble behaviour, and path stability tested.
4–6 months
Early biology & selection delta
Motility enrichment, carryover, and viability data compared across branches.
7–9 months
Head-to-head benchmark
Lead branch tested versus current prep logic; reproducibility and usability scored.
10–12 months
Pilot-ready package
Partner materials, pilot protocol, and commercial narrative prepared for friendly-lab engagement.
Commercial model
Consumables-led economics after proof.
The commercial logic is deliberately simple: participating labs × Select cycles per lab × cartridge price. The scenarios below are post-proof, not day-one entitlement.
$2.5M
25 labs × 200 cycles × $500 cartridge price.
$11.25M
75 labs × 300 cycles × $500 cartridge price.
$37.5M
150 labs × 500 cycles × $500 cartridge price.
Value creation
Prove Select first. Earn the platform later.
Once the wedge becomes technically and operationally credible, Aevrium has multiple routes to value before full standalone commercialization.
Strategic partnerships
Clinical, IVF, and workflow partners can validate the wedge and accelerate adoption once measurable lab-side delta is shown.
Platform licensing
Protected workflow logic and cartridge architecture can support licensing value after the initial wedge is de-risked.
Strategic acquisition
A focused, de-risked fertility workflow platform can attract strategic interest before a full commercial buildout.
Risk discipline
A product-risk investment, not a leap of faith.
The seed program is structured around explicit risks and mitigation rather than broad claims. Investors are underwriting product performance, operational simplicity, and bench credibility.
Risk: technical validation
Selection performance or sensing fidelity may not reach wedge-level relevance.
- Stage the build.
- Benchmark against current prep workflows before claiming wedge proof.
Risk: clinical adoption
Embryology labs may resist anything that feels like workflow disruption.
- Position as an adjunct.
- Score operator burden, recovery practicality, and usability directly.
Risk: single-point failure
Investors may fear the company rises or falls on one front-end geometry.
- Run feasibility and patented branches in parallel.
- Preserve defensibility in workflow and validation-control layers.
Team & governance
Built for focused execution with partner leverage.
The site presents the company without inventing biographies or placeholder names. Team details can be added when leadership, scientific advisors, clinical collaborators, and manufacturing partners are approved for public release.
Operating company
Aevrium Biosystems
Dedicated operating focus on Aevrium Select, the product-proof program, pilot readiness, and investor execution.
IP & venture provenance
Fareban-linked platform
Fareban provides the strategic provenance for Aevrium’s licensed technology position and related operating-company formation.
Execution network
Clinical, engineering & manufacturing
Seed proceeds support fabrication, benchmark testing, usability package development, and friendly-lab pilot preparation.
Investor relations
Underwrite the wedge now. Earn the platform later.
Aevrium is seeking seed investors and strategic partners aligned with disciplined IVF workflow innovation, consumables-led adoption, and patent-safe product development.
Request the investor deck and we’ll be in touch directly.
Email: contact@aevrium.com